Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

[1]  F. Sánchez-Guijo,et al.  Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity , 2019, British journal of haematology.

[2]  M. Vignetti,et al.  Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion‐dependent patients with myelodysplastic syndromes , 2019, European journal of haematology.

[3]  B. Gallie,et al.  Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox , 2019, PloS one.

[4]  K. King,et al.  The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease , 2018, Current Stem Cell Reports.

[5]  L. Lyle,et al.  Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment , 2018, Journal of the advanced practitioner in oncology.

[6]  J. Arnaud,et al.  Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes , 2017, Oncotarget.

[7]  A. Levis,et al.  Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study , 2017, British journal of haematology.

[8]  Aiping Qi,et al.  Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes , 2017, Annals of Hematology.

[9]  E. Anguita,et al.  Transcription Factor GFI1B in Health and Disease , 2017, Front. Oncol..

[10]  N. Gattermann.  Iron overload in myelodysplastic syndromes (MDS) , 2017, International Journal of Hematology.

[11]  N. Mifsud,et al.  The oral iron chelator deferasirox inhibits NF‐κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia , 2015, British journal of haematology.

[12]  Xin Huang,et al.  MicroRNA-146a and MicroRNA-146b Regulate Human Dendritic Cell Apoptosis and Cytokine Production by Targeting TRAF6 and IRAK1 Proteins* , 2014, The Journal of Biological Chemistry.

[13]  M. Vignetti,et al.  Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial) , 2014, European journal of haematology.

[14]  M. Nichelatti,et al.  Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: the experience of the "Rete Ematologica Lombarda". , 2013, Leukemia research.

[15]  J. Hernández-Rivas,et al.  Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes , 2013, Leukemia.

[16]  P. Fenaux,et al.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes , 2012, Haematologica.

[17]  D. Steensma,et al.  Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Schumann,et al.  Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload , 2012, Annals of Hematology.

[19]  Ryan M. O’Connell,et al.  MicroRNA-125b Potentiates Macrophage Activation , 2011, The Journal of Immunology.

[20]  Debashis Sahoo,et al.  MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets , 2010, Proceedings of the National Academy of Sciences.

[21]  D. Cilloni,et al.  Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging , 2010, Haematologica.

[22]  Aadel A. Chaudhuri,et al.  MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output , 2010, Proceedings of the National Academy of Sciences.

[23]  Torsten Haferlach,et al.  Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. , 2009, Blood.

[24]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[25]  S. Okabe,et al.  The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1 , 2009, Cancer science.

[26]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[27]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[28]  Muller Fabbri,et al.  Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock1 , 2007, The Journal of Immunology.

[29]  H. Cario,et al.  Recent developments in iron chelation therapy. , 2007, Klinische Padiatrie.

[30]  J. Carazo,et al.  GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists , 2007, Genome Biology.

[31]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[32]  F. Galactéros.  [Secondary iron overload]. , 1998, La Revue du praticien.

[33]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.